“Targeted therapy for breast cancer requires a better understanding of the role of tumor driving signaling pathways. Leveraging Philips’ OncoSignal technology we show evidence that using certain signaling pathway assays may provide a superior approach to current immunohistochemistry methods to more effectively select patients for specific precision oncology targeted therapy treatments.”
Anthony M. Maglicco, MD, PhD
Founder & CEO, Protean BioDiagnostics, Tampa/ St. Petersburg, Florida, USA
Poster session presentations will be available as PDF e-posters. Links to the e-poster presentations will be available in due time. Abstracts of the posters are included below:
533: Breast cancer IHC subtypes display heterogenous and independent targetable signaling pathway activity profiles- Anthony M. Magliocco, Protean BioDiagnostics, USA
615: Differential pathway analyses of BCG-treated T1HG bladder cancer using Philips OncoSignal: a pilot study- Florus C. de Jong, Erasmus University Medical Center, NL
740: A robust rapid mRNA based test to profile simultaneously ER, AR, PI3K and MAPK functional signaling pathway activity for precision oncology- Eveline den Biezen, Philips Molecular Pathway Diagnostics, NL
741: Characterization of high-grade serous ovarian carcinoma by measuring functional signal transduction pathway activity- Phyllis van der Ploeg, Catharina Hospital, NL
High Tech Campus 11 5656 AE Eindhoven The Netherlands Phone: +31 40 2730155 Email: oncosignal@philips.com
You are about to visit a Philips global content page
Continue